Gyory A N, Bloch M, Burry H C, Grahame R
Br Med J. 1972 Nov 18;4(5837):398-400. doi: 10.1136/bmj.4.5837.398.
In double-blind cross-over studies in 46 patients with rheumatoid arthritis and in 42 patients with osteoarthrosis of the hip, Orudis-a new non-steroidal anti-inflammatory agent-has been shown to be well tolerated and to have comparable therapeutic efficacy with indomethacin when given in equal dosage. Side effects were less severe with Orudis. The results suggest that Orudis will prove valuable in the clinical management of rheumatic diseases.
在针对46名类风湿性关节炎患者和42名髋骨关节炎患者的双盲交叉研究中,一种新型非甾体抗炎药奥鲁地(Orudis)已显示出耐受性良好,并且在给予相同剂量时,其治疗效果与消炎痛相当。使用奥鲁地时副作用较轻。结果表明,奥鲁地在风湿性疾病的临床治疗中将被证明具有重要价值。